Healthcare Industry News: Cytogen
News Release - September 11, 2006
US LABS / Esoterix Names Two Prominent Industry Medical Experts To Chief Diagnostic Consultant and Medical Director PositionsDr. David J. Dabbs and Dr. Dennis P. O'Malley Join Pathology Team
IRVINE, Calif., Sept. 11 (HSMN NewsFeed) -- US LABS / Esoterix, one of the nation's leading specialty testing and cancer diagnostic laboratories, appointed David J. Dabbs, M.D. to the position of chief diagnostic consultant and Dennis P. O'Malley, M.D. to the position of medical director for its Irvine, CA facility, effective immediately.
Dr. David J. Dabbs brings extensive immunohistochemistry experience to US LABS / Esoterix, providing diagnostic consulting and second opinion services in addition to maintaining his current duties as Chief of Pathology at Magee- Womens Hospital and Professor of Pathology at the University of Pittsburgh.
Dr. Dabbs received his medical degree from the Medical College of Ohio and completed his residency and fellowship programs at the University of Washington. Dr. Dabbs has more than twenty years of experience in the surgical pathology of solid tumors, with additional subspecialty-focused interest in the study of tumors of unknown origin, breast carcinoma, gynecologic pathology and tumor cytopathology. Dr. Dabbs offers national workshops in breast pathology and immunohistochemistry and has presented more than 100 papers in peer-reviewed journals and at national meetings. He is the author and editor of the best-selling textbook Diagnostic Immunohistochemistry.
Prior to joining US LABS / Esoterix as Medical Director for its Irvine, CA facility, Dr. Dennis P. O'Malley served as Assistant Professor in the Division of Hematopathology at the Indiana University School of Medicine. Concurrently, Dr. O'Malley also served as Director of the immunohistochemistry laboratory, Associate Director of the molecular pathology laboratory, and Co- Director of the hematopathology fellowship program. His areas of expertise include adult and pediatric bone marrow diseases, lymphomas, cutaneous hematologic disorders, splenic pathology, immunohistochemistry, flow cytometry and molecular diagnostics.
Dr. O'Malley received his medical degree from Loma Linda University School of Medicine and completed fellowships at Duke University and Carolinas Medical Center. Dr. O'Malley is a frequent invited speaker and noted educator, teaching courses for the American Society of Clinical Pathologists, the United States and Canadian Academy of Pathology and the College of American Pathologists. Dr. O'Malley has written numerous articles, book chapters, books and other publications and he most recently co-authored the newly published Illustrated Pathology of the Bone Marrow.
"We're delighted to welcome Drs. Dabbs and O'Malley to our senior pathology team," said David Morgan, Vice President and General Manager of US LABS / Esoterix. "US LABS / Esoterix has a history of attracting high caliber, talented medical experts who are leaders among their peers. These new additions will further strengthen our innovative initiatives to help physicians deliver better patient care through better science."
About US LABS / Esoterix
US LABS / Esoterix is a leading provider of anatomic and clinical pathology reference services focused on high science, superior customer service and innovative new products. Devoted to comprehensive, high-quality, rapid-response cancer testing, US LABS / Esoterix provides diagnostic, prognostic, and predictive services to hospitals, pathologists and clinicians, as well as pharmaceutical and biotechnology companies, other reference laboratories, and managed care organizations. Specimens typically consist of archival tissue, bone marrow or blood, and key testing methodologies include immunohistochemistry, image analysis, flow cytometry, Cytogenetics, FISH and molecular genetics. US LABS / Esoterix also provides industry-leading Web- based capabilities and connectivity solutions that further enhance partnering with clients and help place advanced diagnostic capabilities at the patient's bedside. US LABS / Esoterix is a member of the family of esoteric laboratories that are part of Laboratory Corporation of America Holdings (LabCorp®) (NYSE: LH ).
Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2005, and subsequent SEC filings.
Source: US LABS / Esoterix
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.